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Writing guidelines is hard work. At first sight, it seems simple
to summarize what you believe to be optimal care, but beliefs
should be based on evidence, and that can be hard to identify
in an unbiased way. To reduce the risk of bias when preparing
guidelines, a range of complex methodologies have been
developed. Documents such as the standards of care for chronic
obstructive pulmonary disease (COPD) developed jointly by the
American Thoracic Society (ATS) and European Respiratory
Society in 2004 (1) would not be methodologically acceptable
today. The newer approach has narrowed the scope of the
guidance offered, improving the certainty of the conclusions
drawn at the cost of restricting the number of questions
addressed. Although there have been moves in the guidelines
community to open up the types of evidence considered, most
published guidelines try to identify randomized controlled trials
(RCTs) that offer evidence directly or indirectly with which the
guideline writers can address the clinical question they are
trying to understand. Limiting acceptable answers to questions
for which RCT evidence is present can lead to some strange
anomalies, as we found when writing the European Respiratory
Society/ATS guidance about the management of acute exacerbations
of COPD (2). Although observational studies suggested that
stopping smoking had a beneficial on exacerbation numbers,
we could not make a recommendation about this, because no RCT to
test this idea was ethically possible! However, there are still questions
to consider for which RCT data can provide answers, even in a well-
worked area such as COPD care, and this was the challenge taken
up by a group of North American and British physicians
(pp. e56–e69) who developed the clinical practice guideline on the
pharmacologic management of COPD published in this issue of the
Journal (3).
The expert group considered six questions in relation to
the effectiveness of drug treatment in COPD and assigned a
priority to a range of outcomes that differed between the
interventions. Thus, the risk of pneumonia was prioritized
above efficacy outcomes for questions that related to corticosteroids,
but it is not discussed in connection with long-acting bronchodilator
therapy or opiate use to manage breathlessness. This suggests
that prior knowledge of the field does influence the weighting
given to particular outcomes. Clinical practice guidance needs
to address people other than practicing clinicians with both
patients and payers. The authors explain clearly the interests
of these different stakeholders and use carefully nuanced language
to support their conclusions and what these conclusions might
mean to these interest groups. Whether people reading the
summary of the document will take in these subtleties is unclear,
and this would be a fertile area for further research. Understanding
why guideline writers reached their conclusions is always
interesting, and this is set out in the section on committee
discussion, which, together with a series of research needs,
accompanies each question.
So, what conclusions do the authors draw? First, there is strong
evidence that initial therapy for symptomatic patients with COPD
should be administered with both a long-acting b-agonist (LABA)
bronchodilator and a long-acting muscarinic antagonist (LAMA)
bronchodilator rather than either drug singly. This analysis is in
line with recommendations from the UK National Institute for
Health and Care Excellence, which used the same methodology to
ask a similar question of much the same data (4). Reproducibility is
always a welcome finding in any area of medicine, although the
cost-effectiveness of this treatment policy is likely to vary from
region to region, reflecting local cost issues and healthcare access.
The next two questions looked at the need for additional inhaled
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corticosteroid (ICS) treatment in patients already using inhaled
LABA/LAMA therapy. The authors make a conditional
recommendation to use ICS to prevent exacerbations in patients
receiving LABA1 LAMA therapy who experience one or more
exacerbations but to stop ICS in patients in stable condition while
receiving triple therapy. No recommendation is offered about how
to use the blood eosinophil count to stratify the likely treatment
benefits of ICS, except to support the use of ICS in patients with
one or more exacerbations. This is a complex topic, with relatively
few prospective studies collecting these data (although there are
abundant and consistent post hoc analyses of the relationship
between eosinophil count and exacerbation frequency). Given the
evidence that the relationship between blood eosinophils and
exacerbation frequency is a continuous variable (5) and that the
critical threshold for benefit varies with the number of prior
exacerbations and the background therapy (6), analysis of
this question using the existing guideline methodology was
always going to be tricky. The authors wisely decide against
recommending maintenance oral corticosteroids in patients with
stable COPD, although the evidence on this topic was very
heterogeneous and not collected primarily to determine whether
oral corticosteroids should be continued in the longer term.
Even weaker are the data about the use of opiates to manage
breathlessness, for which a very cautious suggestion that these
might be considered after careful discussion with the patient is
made.
This guideline has considerable strengths, reflecting
the expertise of the clinicians who interpreted the data and
posed the questions as well as the skill of the methodologists
following the well-tested ATS process. Although it is easy
for a “COPD geek” such as myself to be picky about the
individual study selection, the conclusions reached seem
very appropriate and relevant. However, this guideline
does tell us something about the guideline-writing process
and its limitations. One of the most important of these is the
issue of study duration. The data included in the analysis
of opiates ranged from 3 hours to 6 weeks of exposure,
with the longest study identified having a negative result (7).
This is a real concern when opioids show pharmacologically
predictable tachyphylaxis and is highly relevant in a
clinical recommendation. Although there is much emphasis
on RCT data, there is less concern about the purpose for
which the study was conducted and hence about the strength of
the secondary outcomes. Thus, the study by Weir and Burge
was set up to determine whether high-dose ICS had a
physiological effect similar to that of oral corticosteroids
rather to establish whether oral corticosteroids would be
of benefit to all patients with COPD as a maintenance
treatment (8). Perhaps most important, as the authors
acknowledge, this guideline was developed without patient
input, which is a pity, given the ATS’s long history of working
with patient groups. The patient’s perspective on what
the important clinical outcomes are and why this is the
case would be invaluable in any future revision of this
document.
There is clearly a role for the consumer in this process
as well. Guidelines are likely to be most effective when they
meet the needs of the practicing doctor, which may explain
the continuing popularity of broader management strategy
documents such as the one regularly updated by the
Global Initiative for Chronic Obstructive Lung Disease (9).
Understanding where uncertainty exists in the daily office
practice of nonacademic doctors might aid the uptake
of guidelines in general and especially those relating to
COPD. Whatever the source of the information, offering
patients the most appropriate and up-to-date advice
remains an essential part of good clinical management, and
this new clinical practice guideline will certainly help in that
process. n
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